Four Therapeutic Areas encompass all research activities at our Centre. Through programs in neurological & CNS disorders, infectious diseases, cancer, and cardiovascular disease, we're addressing today's most pressing health challenges.
Within each area, a critical mass of multidisciplinary researchers collaborate to resolve core research questions through CDDI-funded Priority-Driven Programs. Each program is designed by lead researchers to achieve essential objectives while meeting tangible progress milestones over three years.
Research Clusters interlink complementary expertise more broadly across the CDDI to rethink how we tackle specific hurdles in understanding and addressing diseases.Â
We advance drug design innovation at the intersection of internationally awarded expertise, novel ideas, and advanced techniques.Â
Research Clusters promote the interlinking of expertise around specific disease problems, targets and drug delivery strategies.
By mapping our capabilities across disciplines, from molecular biology to formulation science, we’re creating new pathways toward overcoming essential research challenges.
Numerous neurodegenerative diseases feature an accumulation of TAR DNA-binding protein 43 aggregates in the brain. The molecular mechanisms of TDP-43 proteinpathies is the basis for a critical knowledge gap, impeding the development of drugs that treat neurodegenerative diseases, including motor-neurone disease.
Led by Professor , the TDP-43 Proteinopathies Research Cluster is cross-disciplinary loci for researchers from 3 faculties and 5 schools. Together, they’re working to identify improved strategies for targeting TDP-43 pathology and related disease-modifying biological pathways.
Advances in in vitro modelling enable researchers to recapitulate human diseases more accurately than ever before via organoid systems and engineered platforms.
Led by Dr , the 3D Cancer Models Research Cluster is a collaborative touchpoint for established and emerging in vitro modelling capabilities at the University. ¸ßÇ帣ÀûƬers are working to elevate and standardise the development of 3D models for application in drug screening, imaging, data analysis and personalised medicine.
The establishment of the Radiopharmaceuticals Research Cluster has arisen from increased activity in radiopharmaceuticals research at the University. The expansion spans design and production, as well as pre-clinical evaluation of imaging, therapeutic and theranostic agents coupled with growth in infrastructure – both in-place and planned at the .
Led by Professor and Professor , the cluster brings together leading researchers and their group members working in the field to consolidate capacity and expertise, build new collaborations and workforce, and strengthen grant opportunities in the future.Â
